Trial reportClinical and experimental immunology2006
Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota.
Trial report in Clinical and experimental immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 6 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- The effect of bovine dairy products and their components on the incidence and natural history of infection: a systematic literature review.Nutrition journal · 2024Pooled it
- Pooled it
- Effects of probiotic supplementation on natural killer cell function in healthy elderly individuals: a meta-analysis of randomized controlled trials.European journal of clinical nutrition · 2020Pooled it
- Probiotics for preventing postoperative infection in colorectal cancer patients: a systematic review and meta-analysis.International journal of colorectal disease · 2019Pooled it
- Pooled it
- Role of probiotics in short bowel syndrome in infants and children--a systematic review.Nutrients · 2013Pooled it
- Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12.Probiotics and antimicrobial proteins · 2021Trial
- Daily Intake of Fermented Milk ContainingNutrients · 2019Trial
- Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers.European journal of nutrition · 2017Trial
- Probiotics-supplemented feeding in extremely low-birth-weight infants.Journal of perinatology : official journal of the California Perinatal Association · 2012Trial
- Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study.Alcohol (Fayetteville, N.Y.) · 2008Trial
- Rethinking probiotics: breaking theGut microbes · 2026Review
- Article
- Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics.Bioscience of microbiota, food and health · 2025Review
- Biotechnological potential of Lacticaseibacillus paracasei Shirota for bioemulsifier, bacteriocin and lipase production.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Lacticaseibacillus casei K11 exerts immunomodulatory effects by enhancing natural killer cell cytotoxicity via the extracellular regulated-protein kinase pathway.European journal of nutrition · 2024Article
- Manipulating the growth environment through co-culture to enhance stress tolerance and viability of probiotic strains in the gastrointestinal tract.Applied and environmental microbiology · 2023Article
- An Overview of Short-Bowel Syndrome in Pediatric Patients: Focus on Clinical Management and Prevention of Complications.Nutrients · 2023Review
- Diverse impact of a probiotic strain,Bioscience of microbiota, food and health · 2023Article
- Live or Heat-KilledInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a placebo-controlled, cross-over trial to examine the effect of Lactobacillus casei Shirota (LcS) on natural killer (NK) cell activity in humans. NK cell activity exhibited a declining trend during the period of placebo ingestion, but NK cell activity increased after intake for 3 weeks of fermented milk containing 4 x 10(10) live LcS. When human peripheral blood mononuclear cells were cultured in the presence of heat-killed LcS, NK cell activity was enhanced. The ability of LcS to enhance NK cell activity and induce interleukin (IL)-12 production was correlated, and the addition of anti-IL-12 monoclonal antibody reduced the enhancement of NK cell activity triggered by LcS. In addition, separation of NK cells from LcS-stimulated monocytes with membrane filter reduced NK cell activity to the intermediate level and almost deprived monocytes of the ability to produce IL-12. These results demonstrate that LcS can enhance NK cell activity in vivo and in vitro in humans, and IL-12 may be responsible for enhancement of NK cell activity triggered by LcS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.